Abstract: The present invention provides a pipecolic acid derivative-containing liposome preparation having has an excellent rapid action capable of coping with an emergent situation such as cerebral infarction. A liposome preparation characterized by comprising, as an active ingredient, a pipecolic acid derivative of the ingredient described in the present specification or a pharmaceutically acceptable salt thereof entrapped into liposomes, wherein lecithin is mainly used as the liposome-forming lipid, said liposome preparation containing no cholesterol as a stabilizer.

Abstract: The present invention provides a method of suppressing ongoing acute allograft rejection. In one embodiment, the method comprises administering to a host experiencing ongoing acute allograft rejection an IL10 inhibitor and an IL2 inhibitor in amounts effective to rescue the allograft from ongoing acute rejection. In another embodiment, the method comprises administering to a host experiencing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor, an IL10 inhibitor in an amount effective to rescue the allograft from ongoing acute rejection.

Abstract: Implants and methods of making same are provided for treatment or prophylaxis of coronary or peripheral vascular constrictions or vascular occlusions, and particularly, stenoses or restenoses, that comprise FK506 in chemically covalently bound, non-covalently bound or physically immobilized form.

Abstract: Present invention is relating to a new use of a compound possessing an inhibitory activity on the production of nitric oxide, for increasing an effect caused by IL-2 inhibitor.

Abstract: The present invention provides a pipecolic acid derivative-containing liposome preparation having has an excellent rapid action capable of coping with an emergent situation such as cerebral infarction.

Abstract: The present invention relates to a novel fatty acid derivative of the following formula: 1

Abstract: A tricyclic compound represented by the general formula (1) and salts thereof are disclosed. ##STR1## A method for producing the tricyclic compound and salts thereof, and an antimicrobial agent containing the tricyclic compound and salts thereof as an active ingredient are also disclosed.

Abstract: This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.

Abstract: The present invention concerns intermediates in the preparation of novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof. The novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof show antimicrobial activity.

Abstract: Macrolide compounds having the structure shown below ##STR1## wherein R.sup.1 is hydroxy or protected hydroxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is methyl, ethyl, propyl or allyl, R.sup.4 is hydroxy, methoxy or oxo, n is 1 or 2 and the symbol of a line and a dotted is a single bond or a double bond, provided that R.sup.2 is not protected hydroxy where R.sup.4 is hydroxy or oxo are used to treat hepatic disease and regenerate liver tissue by facilitating hypertrophy and hyperplasia of hepatocytes.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, lower alkenyl, aryl or ar(lower)alkyl,R.sup.4 is imidazolyl, which may have alkyl or imino-protective group as substituents, or pyridyl,A is lower alkylene, andis single bond or double bond, and pharmaceutically acceptable salts thereof, having 5-HT antagonism.

Abstract: The disclosure deals with pyrazolopyridine compounds of the formula: ##STR1## wherein the variables are defined in the specification. The compounds are useful as a diuretic, anti-hypertensive agent, etc.

Abstract: The invention relates to an antimicrobial compound of the formula: ##STR1## wherein R.sup.1 is amino or a protected amino group,R.sup.2 is lower alkyl, lower alkenyl, carboxy (lower) alkyl or protected carboxy(lower)alkyl,R.sup.3 is hydrogen, lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl, protected amino(lower)alkyl or lower alkanoyl,R.sup.4 is hydrogen, lower alkyl or lower alkylthio, andZ is N or CHor a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to compounds for treatment of nausea and vomiting, of the formula ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkenyl or N,N-di(lower)alkylaminomethyl,R.sup.2 is hydrogen, lower alkyl or halogen,R.sup.3 is imidazolyl or pyridyl, each of which may have substituent(s) selected from lower alkyl and imino-protective group, andR.sup.4 is hydrogen, lower alkyl, lower alkenyl or hydroxy(lower)alkyl and R.sup.5 is hydrogen, hydroxy or lower alkanoyloxy, orR.sup.4 and R.sup.5 are linked together to form an additional bond,or a pharmaceutically acceptable salt thereof.

Abstract: A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.

Abstract: Peptide compounds having Substance P antagonism of the formula: ##STR1## wherein R.sup.1 is lower alkyl, aryl, arylamino, pyridyl, pyrrolyl, pyrazolopyridyl, quinolyl, or a group of the formula: ##STR2## wherein the symbol of a line and dotted line is a single bond or a double bond; X is CH or N; Z is O, S or NH; R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydrogen or hydroxy; R.sup.4 is lower alkyl which may have suitable substituent(s); R.sup.5 is ar(lower)alkyl which may have suitable substituent(s) or pyridyl(lower)alkyl, or R.sup.4 and R.sup.5 are linked together to form benzene-condensed lower alkylene; A is an amino acid residue excepting D-Trp, which may have suitable substituent(s); and Y is bond, lower alkylene or lower alkenylene;and their pharmaceutically acceptable salts are disclosed.

Abstract: The invention relates to a compound of the formula: ##STR1## wherein R.sup.1 is aryl which may have suitable substituents(s), X is --O-- or ##STR2## in which R.sup.3 is hydrogen or lower alkyl, A is a bond or lower alkylene which may have lower alkyl group(s), andR.sup.2 is hydrogen; heterocyclic(lower)alkenoyl which may have carboxy or protected carboxy; heterocycliccarbonyl which may have N,N-di(lower)alkylamino(lower)alkyl, hydroxyimino(lower)alkyl, aryliminio(lower)alkyl, acyl or hydroxy(lower)alkylheterocyclic(lower)alkyl; aroyl which may have 1 to 3 substituent(s) selected from the group consisting of halogen, amino and mono(or di or tri)halo(lower)alkyl; arylcarbamoyl which may have halogen or lower alkoxy; arylamino(lower)alkanoyl; or ar(lower)alkanoyl which may have amino or protected amino,or a pharmaceutically acceptable salt thereof, useful as a cholecystokinin antagonist.

Abstract: The invention relates to a method for the prevention and/or treatment of renal toxicity, nephrosis or nephritis, which comprises administering a pyrazolopyridine compound of the formula: ##STR1## wherein R.sup.1 is aryl, andR.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof to a human being or an animal.

Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl or lower alkenyl, R.sup.2 is hydrogen, lower alkyl, or halogen, R.sup.3 is imidazolyl or pyridyl, each of which may have suitable substituents, and R.sup.4 is hydrogen, lower alkyl, lower alkenyl or hydroxy (lower) alkyl and R.sup.5 is hydrogen, hydroxy, or alkanoyloxy, or R.sup.4 and R.sup.5 are linked together to form an additional bond or novel pyridoindole derivatives which are useful as potent in selective antagonists of 5-HT receptors.

Abstract: The invention relates to novel intermediate compounds for preparation of novel amino acid derivatives having renin inhibiting activity.